权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular mechanisms of BRAF inhibitor induced UPR and autophagy

BRAF抑制剂诱导UPR和自噬的分子机制

基本信息

批准号：
9768184
负责人：
RAVI K AMARAVADI
金额：
$ 35.5万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9768184
关键词：
3-Dimensional 5&apos Untranslated Regions Address Apoptosis Autophagocytosis BRAF gene Binding Biological Biological Assay Biology Biopsy Cell Death Cell Line Cells Chemicals Chloroquine Clinical Trials Critical Pathways Cytoplasm Detection Development Doxycycline Effectiveness Endoplasmic Reticulum Engineering Enrollment Future GRP78 gene Genetic Goals Hypoxia In Situ Knowledge Ligation Link Luciferases MAP Kinase Gene MEK inhibition MEKs Malignant Neoplasms Melanoma Cell Molecular Molecular Chaperones Mus Mutation Oncogenes Pathway interactions Patients Pharmaceutical Preparations Pharmacology Precipitation Proteins RNA Splicing Randomized Clinical Trials Regimen Reporter Reporting Research Personnel Resistance Role Signal Transduction Small Interfering RNA Testing Therapeutic Tissues Tumor Cell Line Variant Video Microscopy Work Xenograft Model Xenograft procedure arm biological adaptation to stress cytotoxicity endoplasmic reticulum stress improved in vivo inhibition of autophagy inhibitor/antagonist knock-down melanoma mutant novel protein protein interaction public health relevance recruit resistance mechanism response targeted treatment three dimensional cell culture tumor

项目摘要

DESCRIPTION (provided by applicant): The dramatic responses observed in patients with BRAF mutant melanoma treated with BRAF inhibitors reflect a major therapeutic breakthrough in melanoma. However, there are multiple resistance mechanisms that arise in patient tumors that limit the effectiveness of BRAF inhibitors. We have found that autophagy is activated in patient tumors and cell lines treated with BRAF inhibitors, and this therapy-associated autophagy protects melanoma cells and contributes to regrowth of tumors. Our previous work establishes that BRAF inhibitors activate autophagy by activating an early ER stress response which in turn gives rise to cytoprotective autophagy. In this proposal, the PI will work closely with the co-investigator, combining their respective expertise in autophagy, melanoma biology and treatment, and the ER stress response to elucidate the mechanistic underpinnings of the mutant BRAF-ER stress-autophagy signaling. Our hypothesis is that certain components of the ER stress pathway are critical for BRAF inhibitor-induced autophagy, and therefore could serve as novel targets for combinations regimens. Our strategy will be to first determine the molecular mechanism that links mutant BRAF with the ER stress response and autophagy (aim 1); then elucidate the biological effects of targeting specific components of the ER stress response or autophagy in BRAFi-induced cell death in 2D and 3D melanoma culture (aim 2); and to characterize the role of BRAFi-induced ER stress and autophagy in vivo using genetic and pharmacological inhibition of ER stress or autophagy in combination with BRAF inhibition (aim 3). The focus of these studies is on the development of a sophisticated understanding of the mechanistic links between these three pathways. The knowledge gained from these studies will increase our understanding about the fundamental biology of BRAF mutant melanoma, the interaction between mutant BRAF and the ER stress response, the role of cytoplasmic GRP78 in the response to targeted therapy, and the mechanisms by which the ER stress response regulates autophagy. Besides these fundamental advances, this project has translational potential because it will investigate these pathways in an enrolling trial of BRAF and autophagy inhibition in BRAF mutant melanoma patients, and it will identify potential new combinations that may be even more effective for future clinical trials.

描述（由申请方提供）：在接受BRAF抑制剂治疗的BRAF突变型黑色素瘤患者中观察到的显著反应反映了黑色素瘤的重大治疗突破。然而，在患者肿瘤中出现的多种耐药机制限制了BRAF抑制剂的有效性。我们已经发现，自噬在用BRAF抑制剂治疗的患者肿瘤和细胞系中被激活，并且这种治疗相关的自噬保护黑色素瘤细胞并有助于肿瘤的再生长。我们以前的工作证实BRAF抑制剂通过激活早期ER应激反应激活自噬，这反过来又引起细胞保护性自噬。在本提案中，PI将与合作研究者密切合作，结合他们各自在自噬、黑色素瘤生物学和治疗以及ER应激反应方面的专业知识，阐明突变型BRAF-ER应激-自噬信号传导的机制基础。我们的假设是，ER应激途径的某些组分对BRAF受体诱导的自噬至关重要，因此可以作为联合治疗方案的新靶点。我们的策略将是首先确定突变BRAF与ER应激反应和自噬联系的分子机制（目的1）;然后阐明靶向ER应激反应或自噬的特定组分在2D和3D黑素瘤培养中BRAFi诱导的细胞死亡中的生物学效应（目的2）;并使用ER应激或自噬的遗传和药理学抑制与BRAF抑制组合来表征BRAF诱导的ER应激和自噬在体内的作用（目的3）。这些研究的重点是对这三种途径之间的机械联系的复杂理解的发展。从这些研究中获得的知识将增加我们对BRAF突变黑色素瘤的基础生物学，突变BRAF和ER应激反应之间的相互作用，细胞质GRP 78在靶向治疗反应中的作用，以及ER应激反应调节自噬的机制的理解。除了这些基本的进展，该项目具有转化潜力，因为它将在BRAF突变黑色素瘤患者的BRAF和自噬抑制的招募试验中研究这些途径，并将确定潜在的新组合，这些组合可能对未来的临床试验更有效。